When Regulations Tighten, Material Strategy Matters
Medical device makers and pharmaceutical packagers face mounting pressure from evolving global regulations, geopolitical disruption, and tighter scrutiny by notified bodies. Material continuity, documentation, and change control are important elements for successful product launches and throughout the entire product life cycle.
This article will demonstrate how a global, pre-tested polymer colorant and additive strategy can reduce supply risk, enable smooth project transfers between regions for global product launches, and connect you with a dedicated healthcare team that has supported medical device, diagnostics, and pharmaceutical packaging customers for more than fifteen years.
Why the Stakes Keep Rising for Healthcare Material Selection
Healthcare manufacturers operate in a climate where regulations governing biocompatibility, traceability, and change control continue to tighten across every major market. Notified bodies and regulators expect deeper material characterization, more comprehensive documentation, and faster response to questions about composition and processing behavior. At the same time, geopolitical friction, freight volatility, and raw material scarcity have made single-source supply strategies fragile, particularly for products that must travel through multiple regions on the way to patients.
These combined pressures put a premium on suppliers that can demonstrate three things consistently:
- Pre-tested materials that align with internationally recognized standards for medical device and pharmaceutical packaging applications
- Documented change control that goes beyond a Chemical Abstracts Service (CAS) number to capture composition shifts that could affect device safety and performance — providing a device placed on the market that matches the one approved by regulators
- A global supply footprint that can absorb regional disruption without forcing a new material qualification
Manufacturers who cannot trace material composition to the lot level, or that depend on a single facility for a critical colorant or additive, expose their submissions and their launch timelines to avoidable risk.
Build Supply Security with Mevopur™ Global Strategy
The Mevopur™ portfolio from Avient is manufactured at several ISO 13485:2016-certified sites located across Europe, North America, and Asia. Each site uses a harmonized raw material range, which supports identical formulations regardless of where you procure them and gives healthcare manufacturers with a backup site that produces to the same quality standards.
Raw materials are pre-tested to the relevant chapters of ISO 10993-1, USP <87>, USP <88> Class VI, USP <661.1>, European Pharmacopeia (EP) 3.1.3 and 3.1.5 (polyolefin), and 3.1.15 (polyester), and the International Council for Harmonisation (ICH) Q3D guidelines on elemental impurities. Drug Master File (Type III) documentation and other regulatory declarations are available on request to support submissions to the FDA and EU notified bodies.
Key practical benefits for converters and original equipment manufacturers (OEMs):
- Procure the same custom colorant or functional additive from the Mevopur™ site closest to your converter, reducing cross-border trade exposure
- Receive change control agreements that go beyond Chemical Abstracts Service (CAS) numbers to address raw material composition shifts that notified bodies now scrutinize
- Maintain consistent material identity, color match, and regulatory documentation across every manufacturing region
Enable Global Product Launches with Regional Project Transfers
Drug delivery devices, diagnostics platforms, and pharmaceutical packaging typically roll out across multiple geographies, often with regional contract manufacturers handling different volumes for different launch windows. Material and color continuity across those launches is a critical factor for brand recognition, color coding, and regulatory submissions.
The harmonized Mevopur raw material range and globally consistent formulation approach lets you transfer a custom colorant or functional additive between regions without re-developing the formulation. That continuity supports:
- Synchronized multi-region launches, where the same color and additive package converts identically in North America, Europe, and Asia
- Production redistribution when a converter expands capacity in a new region or shifts volume to follow a brand’s growth
- Backup-site activation during a freight disruption or trade restriction, with the same Mevopur™ formulation already qualified at an alternate facility
- Faster submission timelines, because the same pre-test documentation and Drug Master File references travel with the project to the new region
This globally harmonized approach turns a multi-region launch from a serial qualification effort into a parallel one, and it removes the typical risk that a regional supplier substitution will trigger a notified body re-assessment late in the program.
Work with a Dedicated Healthcare Polymer Team
A global supply chain delivers its full value when paired with experts who understand healthcare’s unique constraints. Avient’s Mevopur™ portfolio was introduced more than 15 years ago, and the dedicated healthcare team has built deep experience across medical device, in-vitro diagnostic, drug delivery, and pharmaceutical packaging applications.
That team supports customers across the full project lifecycle:
- Application development: Matching the right carrier polymer, pigment chemistry, and additive package to the healthcare product function and use and regulatory requirements
- Regulatory navigation: Translating ISO 10993-1, USP, European Pharmacopeia, and ICH Q3D requirements into practical material selections and pre-test documentation
- Change control management: Operating beyond CAS-level identity to flag and assess raw material shifts that could affect device safety or performance
- Global project transfer: Coordinating the qualification, documentation, and color match between the originating Mevopur™ site and the receiving region
- Sustainability strategy: Advising on bio-based, mass-balance ISCC PLUS, and reduced-material options when carbon footprint reduction is part of the brief
The team also actively tracks evolving regulations and develops compliant products ahead of enforcement, so customers are not scrambling when a new chapter or harmonized standard takes effect.
Choose Concentrates or Ready-to-Use Formulations
Mevopur color and additive products are available in two forms so you can match supply strategy to your application needs:
- Concentrates (masterbatches): Dilute with virgin polymer during conversion to reach the target color or additive level
- Ready-to-use formulations: Color or additive compounds that convert directly without virgin polymer — can help reduce processing variability and support requirements for small quantities
Functional additive options cover UV protection, friction reduction, antioxidants, clarity enhancement, gamma and e-beam sterilization protection, static charge reduction, and laser marking or welding support — all formulated with tested raw materials and manufactured under strict change control management at ISO 13485:2016 sites. For sustainability-driven projects, bio-based concentrates produced under the ISCC PLUS mass balance approach at Malmö, Sweden and Jurong, Singapore can reduce the carbon footprint of the carrier resin, with bio-based content ranging from 70 to 95 percent and reaching 100 percent in select grades.
Move Forward with a Resilient Material Strategy
Today’s regulatory landscape rewards healthcare manufacturers that pair multi-site supply with pre-tested, traceable polymer inputs and deep application expertise. Updated, harmonized standards all push procurement and quality teams toward suppliers that can document material behavior and replicate that documentation in every region where the product launches.
The Mevopur™ portfolio, backed by a dedicated healthcare team, gives you a route to navigate geopolitical, freight, and regulatory changes without requalifying a new material each time a disruption occurs. Build that resilience, talk with an Avient expert now https://www.avient.com/contact-0.
Learn more about our Mevopur™ colorants and additives and Remafin™ EP white colorants for pharmaceutical packaging:
Mevopur™ Healthcare Colorants and Formulations | Avient
Mevopur™ Healthcare Functional Additives | Avient
Mevopur™ Healthcare Bio-based Polymer Solutions | Avient
Remafin™ EP White Colorants | Avient
